Skip to main content

Lupus

      9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylate
      6 months ago
      9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
      #EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Po
      #EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
      SLE Preview: abolishing refractory with CAR-T and better B-cell therapies

      Despite advancements, some SLE patients rema
      6 months ago
      SLE Preview: abolishing refractory with CAR-T and better B-cell therapies Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years. https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
      Pregnancy in lupus patients is a complex situation, posing significant concerns for both patients and physicians due to the risk of adverse pregnancy outcomes. These outcomes can range from increased…
      #EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ika
      6 months 1 week ago
      #EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
      🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry

      ➡️Cognitive symptoms si
      6 months 1 week ago
      🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry ➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs ➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL @RheumNow #EULAR2024
      #EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab
      6 months 1 week ago
      #EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
      ×